TL;DR: Rarely do they think about what happens to a 10% glycolic acid formula sitting in a warehouse in Dubai for six weeks in August, or how an airless pump’s polypropylene dip tube behaves after 90 days of contact with a pH 3.2 mandelic-salicylic blend
TL;DR: At a fixed total glycolic acid concentration of 10%, shifting pH from 3.5 to 4.0 reduces the free acid fraction from roughly 76% to 55%
Key Technical Parameters #
Three scenarios break acid exfoliant formulations more reliably than any others: temperature cycling during shipping and retail storage, co-application with oxidizing or reactive chemical systems, and sustained mechanical stress from pump or airless dispenser components. Brand partners briefing us on acid serums and toners usually focus on in-vitro pH data and consumer patch results. Rarely do they think about what happens to a 10% glycolic acid formula sitting in a warehouse in Dubai for six weeks in August, or how an airless pump’s polypropylene dip tube behaves after 90 days of contact with a pH 3.2 mandelic-salicylic blend. This guide covers those three operating conditions with data from our own production and stability records, because they’re where the gap between lab approval and market complaint lives.
The Specification That Matters Most — Free Acid Fraction Under Dynamic Conditions #
Most incoming specs for acid actives focus on total acid concentration and initial pH. Those two numbers are necessary but not sufficient. What actually drives exfoliation performance and safety margin is the free acid fraction, meaning the proportion of acid in its protonated, membrane-penetrating form, measured under the temperature and pH conditions the formula will actually experience across its shelf life.
At a fixed total glycolic acid concentration of 10%, shifting pH from 3.5 to 4.0 reduces the free acid fraction from roughly 76% to 55%. That’s a meaningful drop in active delivery, and it happens silently during temperature cycling without any visible change to the formula. Our internal stability protocol, QC-S14, flags pH drift exceeding ±0.2 units over an 8-week accelerated cycle (40°C/75% RH) as a Category B instability event — not because the formula looks different, but because the bioavailable acid fraction has shifted outside the validated range.
Temperature cycling specifically is underestimated. Retail and logistics chains in Southeast Asia, the Middle East, and parts of Latin America routinely expose product to 35–45°C ambient. A formula passing stability at a steady 40°C can behave differently under a 15°C–40°C diurnal cycle. The repeated expansion and contraction affects emulsion droplet structure in leave-on acid creams, and in water-based toners it accelerates the interaction between free acid and any carbomer or xanthan thickener in the system. We’ve observed viscosity loss of 18–22% in carbomer-thickened glycolic toners after 10 thermal cycles between 10°C and 45°C — not a cosmetic failure on the surface, but enough to affect consumer pour behavior and dosing.
The SCCS Scientific Opinion on AHA safety ties the consumer risk assessment directly to free acid fraction and product pH, not just total concentration. If you’re targeting the EU market, that’s the document that matters for your safety dossier, not just the raw material spec sheet.
For leave-on formats, the practical threshold we work to is maintaining free acid fraction within ±10% of the validated baseline across the full claimed shelf life under realistic storage conditions — not just the ICH 40°C/75% RH static chamber. That distinction has caught failures we would have missed otherwise.
Supplier Qualification — What to Request and What the Response Tells You #
When we qualify a new AHA or BHA raw material supplier for acid exfoliation systems, the first document we ask for is a Certificate of Analysis that includes heavy metal panel results (lead, arsenic, mercury, cadmium) per EU Cosmetics Regulation 1223/2009 Annex II prohibited substance limits — and we ask for it on the specific manufacturing batch we’re sampling, not a generic annual test. The response time matters. A supplier who delivers full heavy metal data within 48 hours of request has a quality management system built around traceability. A supplier who takes two weeks and sends a generalized document from a different lot is telling you something about their process, and it’s not good.
Second request: color stability data under UV exposure. Glycolic acid at high purity is nearly colorless, but crude grades or those with residual organic impurities will yellow at pH below 3.5 when exposed to UV. Ask for a 72-hour UV chamber test (broad spectrum, 1.2 W/m² UV-A) on a 12% aqueous solution, unbuffered, open-vessel. Very few suppliers have run this. The ones who have — and who share the data — are the ones worth developing further.
Third: we always ask for polymerization index on glycolic acid specifically. High-purity glycolic acid should have a polymerization index below 0.8 (measured by GPC against polystyrene standards). Above that threshold, we start seeing anomalous viscosity behavior in aqueous gel systems that is almost impossible to diagnose without the upstream material data. We’ve had two projects where a formula performing well with Supplier A’s glycolic failed to reach target viscosity with Supplier B’s — same declared purity, same concentration. The polymerization index was different. Supplier B’s material had a PI of 1.4.
For salicylic acid, the critical qualifier is particle size distribution, not purity. Salicylic acid is practically insoluble in water at room temperature (0.2 g/100 mL at 20°C), so most aqueous and hydroalcoholic systems are technically dispersions, not true solutions. A D90 above 25 µm creates gritty texture and uneven skin deposition. Ask for laser diffraction data on the specific grade you’re sampling. If the supplier doesn’t have it, they’re not the right partner for suspension-type exfoliant formats.
One more thing we now include in every new supplier AVL gate review: a 90-day container compatibility test using the intended packaging material (PP, HDPE, and glass are different stories). Acids interact with container walls over time, and the migration data matters for both safety and aesthetic stability. Some suppliers will flag this as outside their scope. Fine. We run it ourselves. But asking the question tells you whether they’ve thought about end-use conditions at all.
Cost-Performance Trade-Offs in Acid Exfoliant Systems #
Glycolic acid is the cheapest AHA per active gram. That’s true at every volume we buy, from 50 kg development quantities up to 2,000 kg production runs. The cost delta versus lactic acid is typically 30–45% in favor of glycolic at comparable purity grades. For brands targeting a low-cost-per-unit position, glycolic is the rational choice — and for a rinse-off format at pH 3.8–4.2, the performance difference versus lactic acid at equivalent free acid fraction is genuinely small.
Where glycolic becomes the wrong choice is in leave-on formats for compromised or reactive skin, and in any product where the on-pack claim references “gentle” or “suitable for sensitive skin.” Glycolic’s smaller molecular weight (76 g/mol versus lactic’s 90 g/mol) means faster epidermal penetration. At equivalent free acid concentration, glycolic produces more erythema in standardized patch tests. For a brand whose positioning depends on tolerability differentiation, paying a 35% premium for lactic acid is not irrational — it’s directly supporting the claim.
Mandelic acid sits at the expensive end of the AHA range, and honestly we’re skeptical of some of the supplier marketing around its specificity for hyperpigmentation. The larger molecular weight (152 g/mol) slows penetration, which does improve tolerability, but the claim that this makes it uniquely efficacious for melanin suppression isn’t well-supported by head-to-head data against lactic at matched free acid fractions. We still formulate with it when the brief calls for it, but we’d push back on any brand trying to build a premium price point on mandelic acid science alone.
PHAs like gluconolactone are the clearest counterargument to the “cheaper is fine” logic. Per gram of active, gluconolactone costs 3–5× more than glycolic. For a standard 5% exfoliant serum, the raw material cost impact is real. But for a barrier-repair positioning, or a post-procedure product where stinging complaints would be a brand crisis, the tolerability data for PHAs is strong enough that the cost premium is warranted. A randomized controlled study (n=33, 12 weeks, twice-daily application) comparing 8% gluconolactone versus 8% glycolic in rosacea-prone subjects showed the gluconolactone group had a 44% lower rate of transient erythema at the 4-week timepoint, with comparable exfoliation outcomes at week 12. That’s the kind of data that justifies the cost difference to a brand owner.
Our acid exfoliation technology category covers the full range of AHA, BHA, and PHA actives we work with — the cost and performance positioning varies significantly by format and target consumer.
Technical Deep-Dive — Acid Exfoliants Under Mechanical and Chemical Stress in Packaging #
This is the section most brand development teams skip, and it’s where we’ve seen the most preventable product failures.
Airless pump systems are increasingly specified for acid serums because they reduce oxidation exposure and deliver metered dosing. The mechanical stress issue comes from the piston-and-tube mechanism in contact with the formula across the full product lifespan — typically 100–200 pump actuations for a 30 mL bottle. At pH below 3.5, polypropylene dip tubes show measurable extractable leaching of low-molecular-weight oligomers into aqueous acid systems over 12 weeks at 40°C. The amounts are below EU Cosmetics Regulation 1223/2009 limits for most compounds, but the impact on formula aesthetics — slight cloudiness, subtle odor shift — is enough to generate consumer complaints.
We now run all acid formulas below pH 3.8 through a packaging compatibility protocol that includes 12-week migration testing in the actual fill-volume container with real pump actuations at weeks 0, 4, 8, and 12. That protocol costs time and adds 3–4 weeks to the development calendar. Brands who skip it to hit a launch date sometimes regret it.
The chemical stress scenario is more nuanced. We’re increasingly briefed on formulas combining acid exfoliants with encapsulated actives — retinol, niacinamide, or ascorbic acid derivatives. The failure mode here is shell integrity. Most encapsulation systems for sensitive actives are designed for near-neutral pH. At pH 3.2–3.8, typical of an AHA-dominant serum, maltodextrin or β-cyclodextrin shells degrade measurably faster. In our trials, maltodextrin-encapsulated retinol in a 10% lactic acid formula at pH 3.6 showed 38% shell degradation by week 6 at 40°C, versus 12% degradation in the same formula at pH 4.5. That’s not a formulation failure — it’s a specification mismatch. The encapsulation system was not designed for that pH environment.
| Condition | Glycolic 10% pH 3.5 | Lactic 10% pH 3.8 | Mandelic 8% pH 4.0 |
|---|---|---|---|
| Viscosity drift after 10 thermal cycles (10–45°C) | –21% (carbomer gel) | –11% (carbomer gel) | –6% (carbomer gel) |
| PP dip tube extractables at 12 weeks, 40°C | Detectable trace oligomers | Below detection threshold | Below detection threshold |
| Retinol encap. shell integrity at 6 weeks, 40°C | 38% degradation | 22% degradation | 14% degradation |
| Free acid fraction shift (pH 3.5→4.0) | –28% relative | –19% relative | –12% relative |
Measured across development batches at our Guangzhou facility, 2022–2024. Carbomer system: Carbopol 980 at 0.4%, NaOH-neutralized to target pH prior to acid addition.
The pressure and load piece comes up less frequently but matters for certain formats. Tube packaging for acid creams and balms creates a sustained hydrostatic pressure at the crimp seal. At pH below 3.5 and temperatures above 35°C, we see accelerated seal degradation with certain laminate grades. The failure point is almost always at the innermost PE layer adhesion, not the barrier film. Three out of eight tube samples across one client project showed microleakage at the crimp by week 10 of accelerated stability. The brand had already run EU safety assessment on the formula — the formula was fine. The packaging was wrong.
For our encapsulation technology work with acid systems, the pH floor we now specify as a minimum qualification criterion is 3.8 for any shell system that isn’t specifically validated for low-pH environments. Below that, the encapsulation adds cost but degrades too fast to add meaningful active protection. We’re still working on lower-pH-compatible shell systems — our current approach uses ethyl cellulose polymer shells with pH-resistant plasticizer, and early data at 12 weeks looks promising, but we don’t have the 24-month real-time data to call it validated yet.
Formulation Notes for Brand Partners #
When you brief us on an acid exfoliation product, the first three questions are: which market, which format, and what’s the on-pack narrative? Those three variables change the entire qualification path.
A 5% glycolic toner for the US market targeting Gen Z online retail is a different project from a 10% lactic serum for EU pharmacy distribution — not just in regulatory documentation burden, but in the packaging compatibility testing, the stability protocol design, and the pH range we’ll defend. The FDA Cosmetics Guidelines allow more formulation latitude than the EU dossier requirement under Regulation 1223/2009, but the US market has its own retailer requirements that often exceed the regulatory floor.
The brief mistake we see most often is brands specifying acid concentration first and pH second, when the real performance and safety variable is the free acid fraction that results from the combination of both. We had one project where a brand wanted “glycolic 7%” on-pack and specified pH 4.5 — which delivers a free acid fraction of roughly 24%. That’s a moisturizer with mild exfoliant benefit, not an active exfoliator. We reframed the brief around target free acid fraction (40–50% for a moderate-efficacy leave-on) and worked backward to concentration and pH from there. The formula ended up at 9% glycolic, pH 3.9. Different brief, better outcome.
Timeline: lab samples in 2–3 weeks from receipt of confirmed brief, accelerated stability initiated at sample approval (4–8 weeks, 40°C/75% RH per ICH Q1B), 24-month real-time stability running concurrently from the same date. Packaging compatibility runs parallel to stability, not after.
Frequently Asked Questions #
We want 10% glycolic on pack at pH 4.5 — is that actually doing anything?
A: At pH 4.5, roughly 20–24% of glycolic acid is in the free acid form, which is the active fraction. You’ll get mild cell turnover over 4–6 weeks of daily use, but you won’t see the keratinolytic response most consumers expect from a “10% AHA” product. If efficacy is the point, we’d recommend revisiting the pH target. If tolerability and gentle daily use is the positioning, then pH 4.5 with 10% glycolic is actually a reasonable brief — just communicate that to the consumer clearly.
Does the EU cap acid exfoliants at 10%? We’ve seen conflicting information.
A: The SCCS Scientific Opinion and EU Cosmetics Regulation 1223/2009 don’t set a single hard cap, but the SCCS opinion ties acceptable use concentrations to product category and pH in combination. Leave-on products above 10% AHA at pH below 3.5 require a substantiated safety dossier that most brands can’t easily produce. Rinse-off products get more latitude. The practical ceiling for leave-on without significant safety work is 10% at pH 3.5–4.5, and we advise staying above pH 3.5 for EU positioning.
We ran 8-week accelerated stability and it passed — why did we get consumer complaints at month 7?
A: Accelerated stability at 40°C/75% RH is predictive but not infallible, especially for packaging compatibility issues. The most common late-failure mode we see in acid systems is gradual extractable migration from pump or tube components that shows up in the formula as a faint odor shift or slight turbidity — both perceptible to consumers before any analytical threshold is breached. An 8-week chamber test won’t catch a 6-month migration trend. That’s why we run parallel packaging contact tests at 12 and 24 weeks, not just the formula in isolation.
What’s your MOQ for an acid serum and how long does a typical development project take?
A: MOQ for acid-format products starts at 1,000 units for most configurations. Full development from confirmed brief to approved pilot batch typically runs 10–14 weeks, accounting for 2–3 weeks of formulation, 4–8 weeks of accelerated stability, and production scheduling. If the formula requires specialized packaging compatibility validation — which most low-pH acid serums do — add 3–4 weeks.
We’re combining 5% niacinamide with 8% glycolic — anything we should know before briefing that in?
A: The niacinamide-glycolic combination is actually more stable than the old niacinamide-ascorbic acid concern. The real issue is that at pH 3.5–4.0 (typical for 8% glycolic), niacinamide undergoes slow hydrolysis to nicotinic acid over time — faster at elevated temperatures. By month 9 at 35°C, we’ve measured nicotinic acid accumulation at levels that can cause transient flushing in some users. It’s not dangerous, but it generates consumer calls. Our approach is either to buffer the formula above pH 4.2 (which reduces glycolic free acid fraction) or to introduce niacinamide in an encapsulated form that releases at near-neutral skin pH. Both are viable — the choice depends on whether the brand prioritizes glycolic efficacy or niacinamide payoff.
Have a product concept in mind? Contact our formulation team to request a complimentary brief review.
